Core Viewpoint - The increasing prevalence of retinal diseases due to global aging presents significant challenges in ophthalmic healthcare, necessitating advanced surgical solutions like ophthalmic surgical robots to meet the precision demands of treatments [2][6][28]. Group 1: Industry Context - The rise in retinal diseases such as macular degeneration and diabetic retinopathy is linked to an aging population, leading to a higher demand for precise and minimally invasive surgical interventions [2]. - Traditional manual surgical methods are limited by human factors such as hand tremors, making it difficult to achieve the required precision for procedures involving small blood vessels [6][10]. Group 2: Technological Advancements - Ophthalmic surgical robots developed by companies like Xianwei Medical are designed to overcome the limitations of manual surgery, offering high precision and stability essential for complex procedures [6][12]. - Key technological features of these robots include dual-arm control, micron-level positioning accuracy, and advanced algorithms for motion scaling and dynamic compensation [11][12]. Group 3: Product Development - Xianwei Medical has introduced the first domestic eyelid gland thermal pulsation treatment device, addressing the rising incidence of dry eye syndrome caused by meibomian gland dysfunction [23][25]. - The device utilizes direct heating technology to effectively treat the underlying causes of dry eye, offering a more efficient and safer alternative to existing treatments [25][27]. Group 4: Clinical Validation and Market Strategy - The thermal pulsation device has undergone clinical validation, demonstrating significant improvements in meibomian gland secretion and prolonged relief from dry eye symptoms [27]. - Xianwei Medical's strategy includes diversifying its product offerings to stabilize cash flow and mitigate market uncertainties, with the thermal pulsation device serving as a quick-to-market solution [27][28]. Group 5: Future Outlook - The company aims to reshape the treatment landscape for retinal diseases and dry eye syndrome through continuous innovation and a focus on clinical needs, leveraging intelligent technology for enhanced patient outcomes [28][29].